[go: up one dir, main page]

EP4506017A3 - Improved peptide pharmaceuticals for treatment of nash and other disorders - Google Patents

Improved peptide pharmaceuticals for treatment of nash and other disorders Download PDF

Info

Publication number
EP4506017A3
EP4506017A3 EP24195508.7A EP24195508A EP4506017A3 EP 4506017 A3 EP4506017 A3 EP 4506017A3 EP 24195508 A EP24195508 A EP 24195508A EP 4506017 A3 EP4506017 A3 EP 4506017A3
Authority
EP
European Patent Office
Prior art keywords
nash
disorders
treatment
improved peptide
peptide pharmaceuticals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24195508.7A
Other languages
German (de)
French (fr)
Other versions
EP4506017A2 (en
Inventor
John J. Nestor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mederis Diabetes LLC
Original Assignee
Mederis Diabetes LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mederis Diabetes LLC filed Critical Mederis Diabetes LLC
Publication of EP4506017A2 publication Critical patent/EP4506017A2/en
Publication of EP4506017A3 publication Critical patent/EP4506017A3/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)

Abstract

The disclosure provides peptide products comprising a peptide covalently attached to a surfactant moiety which have improved properties, including increased duration of action and bioavailability. The peptide products are useful for treating insulin resistance, diabetes, obesity, metabolic syndrome and cardiovascular diseases, and conditions associated therewith, such as NASH and PCOS.
EP24195508.7A 2018-01-03 2019-01-03 Improved peptide pharmaceuticals for treatment of nash and other disorders Pending EP4506017A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862613396P 2018-01-03 2018-01-03
EP19704897.8A EP3735295B1 (en) 2018-01-03 2019-01-03 Improved peptide pharmaceuticals for treatment of nash and other disorders
PCT/US2019/012194 WO2019136158A1 (en) 2018-01-03 2019-01-03 Improved peptide pharmaceuticals for treatment of nash and other disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP19704897.8A Division EP3735295B1 (en) 2018-01-03 2019-01-03 Improved peptide pharmaceuticals for treatment of nash and other disorders

Publications (2)

Publication Number Publication Date
EP4506017A2 EP4506017A2 (en) 2025-02-12
EP4506017A3 true EP4506017A3 (en) 2025-05-14

Family

ID=65409472

Family Applications (2)

Application Number Title Priority Date Filing Date
EP24195508.7A Pending EP4506017A3 (en) 2018-01-03 2019-01-03 Improved peptide pharmaceuticals for treatment of nash and other disorders
EP19704897.8A Active EP3735295B1 (en) 2018-01-03 2019-01-03 Improved peptide pharmaceuticals for treatment of nash and other disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP19704897.8A Active EP3735295B1 (en) 2018-01-03 2019-01-03 Improved peptide pharmaceuticals for treatment of nash and other disorders

Country Status (17)

Country Link
US (3) US11541028B2 (en)
EP (2) EP4506017A3 (en)
JP (2) JP7670749B2 (en)
KR (2) KR102784507B1 (en)
CN (1) CN111818971A (en)
AU (2) AU2019205905B2 (en)
BR (1) BR112020013644A2 (en)
CA (1) CA3086918A1 (en)
DK (1) DK3735295T3 (en)
ES (1) ES3002666T3 (en)
FI (1) FI3735295T3 (en)
HU (1) HUE069178T2 (en)
IL (2) IL311775A (en)
MX (1) MX2020006999A (en)
PL (1) PL3735295T3 (en)
PT (1) PT3735295T (en)
WO (1) WO2019136158A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3566711A1 (en) * 2011-05-18 2019-11-13 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
KR102213907B1 (en) * 2012-11-20 2021-02-09 메더리스 다이어비티즈, 엘엘씨 Improved peptide pharmaceuticals for insulin resistance
PL3155017T4 (en) * 2014-05-28 2024-06-17 Mederis Diabetes, Llc Improved peptide pharmaceuticals for insulin resistance
CA3086918A1 (en) * 2018-01-03 2019-07-11 Mederis Diabetes, Llc Improved peptide pharmaceuticals for treatment of nash and other disorders
GB2576705A (en) * 2018-08-17 2020-03-04 E Miller Norman Improvements in or relating to organic material
CA3168001A1 (en) * 2020-02-21 2021-08-26 Spitfire Pharma Llc Glp-1r and gcgr agonists, formulations, and methods of use
CN111514276B (en) * 2020-06-29 2021-07-27 黑龙江中医药大学 Application of short peptide Asp-His-Tyr in preparation of medicine for treating polycystic ovary syndrome
JP2024500324A (en) * 2020-12-07 2024-01-09 スピットファイア ファーマ エルエルシー Treatment regimens and methods for lowering blood sugar and/or weight using GLP-1R and GCGR balanced agonists
US12171806B2 (en) 2021-09-28 2024-12-24 Spitfire Pharma Llc Therapeutic regimens and methods for lowering blood glucose and/or body weight using GLP-1R and GCGR balanced agonists
WO2022178366A1 (en) * 2021-02-21 2022-08-25 Spitfire Pharma Llc Glp-1r, gip-r and/or gcgr agonists, formulations, and methods of use
CN113171446B (en) * 2021-05-06 2022-03-29 合肥天汇孵化科技有限公司 Liraglutide compositions and uses thereof
CN114767665B (en) * 2021-06-11 2023-10-10 同济大学 Use of 5-tetradecyloxy-2-furancarboxylic acid in preparation of medicament for treating psoriasis-like dermatitis
EP4154913A1 (en) 2021-09-28 2023-03-29 Københavns Universitet Conjugates of glucagon and ampk activators
WO2024017964A1 (en) * 2022-07-20 2024-01-25 Actelion Pharmaceuticals Ltd Injectable pharmaceutical composition comprising a diphenylpyrazine derivative
AU2023316471A1 (en) * 2022-07-29 2025-01-30 The Regents Of The University Of California Compositions and methods for treating metabolic disorders
CN115429871B (en) * 2022-09-30 2025-03-18 中南大学湘雅二医院 New uses of semaglutide
TW202444370A (en) * 2023-03-23 2024-11-16 瑞士商艾克泰聯製藥有限公司 Pharmaceutical composition comprising a diphenylpyrazine derivative

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012158965A2 (en) * 2011-05-18 2012-11-22 Mederis Diabetes, Llc Improved peptide pharmaceuticals for insulin resistance
WO2014081864A1 (en) * 2012-11-20 2014-05-30 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
US20150290334A1 (en) * 2012-11-20 2015-10-15 Mederis Diabetes Llc Peptide pharmaceuticals for insulin resistance
WO2015184177A1 (en) * 2014-05-28 2015-12-03 Mederis Diabetes, Llc Improved peptide pharmaceuticals for insulin resistance
WO2016065090A1 (en) * 2014-10-24 2016-04-28 Merck Sharp & Dohme Corp. Co-agonists of the glucagon and glp-1 receptors

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3219656A (en) 1963-08-12 1965-11-23 Rohm & Haas Alkylpolyalkoxyalkyl glucosides and process of preparation therefor
US3839318A (en) 1970-09-27 1974-10-01 Rohm & Haas Process for preparation of alkyl glucosides and alkyl oligosaccharides
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (en) 1979-07-11 1985-06-05 味の素株式会社 blood substitute
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
AT382381B (en) 1984-10-02 1987-02-25 Oesterr Zuckerfab Evidenz METHOD FOR PRODUCING NEW INTERFACE CHARACTERISTIC CARBOHYDRATE DERIVATIVES
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5252318A (en) 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
US5574142A (en) 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
US5661130A (en) 1993-06-24 1997-08-26 The Uab Research Foundation Absorption enhancers for drug administration
JPH1160598A (en) 1997-08-15 1999-03-02 Asahi Glass Co Ltd Opioid-like peptide
US6720407B1 (en) 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
RU2181729C1 (en) 2000-09-20 2002-04-27 Калюжин Олег Витальевич Muramic acid derivatives
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6864069B2 (en) 2001-10-05 2005-03-08 Bayer Pharmaceuticals Corporation Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
SG177002A1 (en) 2001-10-10 2012-01-30 Novo Nordisk As Remodeling and glycoconjugation of peptides
US6881829B2 (en) 2002-04-26 2005-04-19 Chimeracom, L.L.C. Chimeric hybrid analgesics
JP4334480B2 (en) 2003-03-19 2009-09-30 ザ ジェネラル ホスピタル コーポレイション A conformationally constrained parathyroid hormone using an α-helix stabilizer
KR101135244B1 (en) * 2007-11-29 2012-04-24 한미사이언스 주식회사 A pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
EP2457580A1 (en) 2004-08-25 2012-05-30 The UAB Research Foundation Absorption enhancers for drug administration
US20110257096A1 (en) 2004-08-25 2011-10-20 Aegis Therapeutics, Inc. Compositions for drug administration
CN102772787A (en) 2004-11-12 2012-11-14 诺和诺德公司 Stable formulations of insulinoptropic peptides
ITRM20040607A1 (en) 2004-12-15 2005-03-15 Biogen S R L ANALOGUES OF THE DERMORFINA WITH ANALGESIC ACTIVITY.
WO2006096426A2 (en) 2005-03-03 2006-09-14 The Board Of Trustees Of The University Of Illinois Targeted drug delivery of pain and addiction therapies using opioid receptor-mediated internalization
WO2006121860A2 (en) 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use
WO2007002465A2 (en) 2005-06-23 2007-01-04 Rapid Pharmaceuticals, Llc Stabilizing alkylglycoside compositions and methods thereof
PT1767545E (en) 2005-09-22 2010-02-05 Biocompatibles Uk Ltd Glp-1 (glucagon-like peptide-1) fusion polypeptides with increased peptidase resistance
WO2007060692A2 (en) 2005-11-24 2007-05-31 Brain N' Beyond Biotech Pvt. Ltd. Compositions for increasing bioavailability of peptides or proteins and method thereof
US7425542B2 (en) 2006-06-23 2008-09-16 Aegis Therapeutics, Inc. Stabilizing alkylglycoside compositions and methods thereof
US7998927B2 (en) 2006-06-23 2011-08-16 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US8173594B2 (en) 2006-06-23 2012-05-08 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
WO2008052043A2 (en) 2006-10-24 2008-05-02 Cogenesys, Inc. Opioid receptor agonist fusion proteins
EP1961765A1 (en) 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
AU2008216265B2 (en) 2007-02-15 2014-04-03 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
AU2008318876B2 (en) 2007-10-30 2014-05-15 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and GLP-1 agonist activity
CA2708762A1 (en) 2007-12-11 2009-06-18 Conjuchem Biotechnologies Inc. Formulation of insulinotropic peptide conjugates
JP2011518200A (en) 2008-04-22 2011-06-23 メルク フロスト カナダ リミテツド Novel substituted heteroaromatic compounds as inhibitors of stearoyl-coenzyme A delta-9 desaturase
PA8830501A1 (en) 2008-06-17 2010-07-27 Univ Indiana Res & Tech Corp GLUCAGON / GLP-1 RECEIVER CO-AGONISTS
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
CA2786934A1 (en) 2010-01-20 2011-07-28 Zealand Pharma A/S Treatment of cardiac conditions
BR112012024379A2 (en) 2010-03-26 2017-01-10 Novo Nordisk As "glucagon peptides, their use as well as pharmaceutical composition"
KR101382593B1 (en) * 2010-07-21 2014-04-10 한미사이언스 주식회사 Novel long-acting glucagon conjugate and pharmaceutical composition comprising the same for the prevention and treatment of obesity
EP2654773B1 (en) 2010-12-22 2018-10-03 Indiana University Research and Technology Corporation Glucagon analogs exhibiting gip receptor activity
KR101453037B1 (en) 2011-03-23 2014-10-21 주식회사 엘지화학 Electrode assembly for secondary battery preparation method of electrode assembly thereof
EP3566711A1 (en) 2011-05-18 2019-11-13 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
BR112015025464A2 (en) 2013-04-18 2017-10-10 Novo Nordisk As stable, prolonged glp-1 / glucagon receptor coagonists for medical use
EP3080151A1 (en) * 2013-12-13 2016-10-19 Sanofi Exendin-4 peptide analogues
TWI802396B (en) * 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 Use of a long acting glp-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease
US20190161431A1 (en) 2015-02-15 2019-05-30 Avocet IP limited Apparatus and method for continuous production of polyethylene glycol dinitrate
CN106046145B (en) * 2016-04-22 2022-11-04 深圳市图微安创科技开发有限公司 GLP-1R/GCGR dual-target agonist polypeptides for treating fatty liver disease, hyperlipidemia and arteriosclerosis
CA3086918A1 (en) * 2018-01-03 2019-07-11 Mederis Diabetes, Llc Improved peptide pharmaceuticals for treatment of nash and other disorders

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012158965A2 (en) * 2011-05-18 2012-11-22 Mederis Diabetes, Llc Improved peptide pharmaceuticals for insulin resistance
WO2014081864A1 (en) * 2012-11-20 2014-05-30 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
US20150290334A1 (en) * 2012-11-20 2015-10-15 Mederis Diabetes Llc Peptide pharmaceuticals for insulin resistance
WO2015184177A1 (en) * 2014-05-28 2015-12-03 Mederis Diabetes, Llc Improved peptide pharmaceuticals for insulin resistance
WO2016065090A1 (en) * 2014-10-24 2016-04-28 Merck Sharp & Dohme Corp. Co-agonists of the glucagon and glp-1 receptors

Also Published As

Publication number Publication date
EP4506017A2 (en) 2025-02-12
RU2020125550A (en) 2022-02-03
KR102784507B1 (en) 2025-03-19
EP3735295A1 (en) 2020-11-11
DK3735295T3 (en) 2024-11-25
JP2025118652A (en) 2025-08-13
IL311775A (en) 2024-05-01
US20250281450A1 (en) 2025-09-11
CN111818971A (en) 2020-10-23
AU2019205905B2 (en) 2024-12-12
PL3735295T4 (en) 2025-01-20
US12257229B2 (en) 2025-03-25
MX2020006999A (en) 2020-12-10
US11541028B2 (en) 2023-01-03
ES3002666T3 (en) 2025-03-07
PL3735295T3 (en) 2025-01-20
KR20250043579A (en) 2025-03-28
IL275777A (en) 2020-08-31
HUE069178T2 (en) 2025-02-28
IL275777B1 (en) 2024-05-01
US20230218564A1 (en) 2023-07-13
BR112020013644A2 (en) 2020-12-01
JP2023153115A (en) 2023-10-17
WO2019136158A1 (en) 2019-07-11
CA3086918A1 (en) 2019-07-11
AU2019205905A1 (en) 2020-07-30
JP7670749B2 (en) 2025-04-30
FI3735295T3 (en) 2024-11-20
IL275777B2 (en) 2024-09-01
JP2021509892A (en) 2021-04-08
PT3735295T (en) 2024-12-11
AU2025200349A1 (en) 2025-03-27
US20200352900A1 (en) 2020-11-12
KR20200106173A (en) 2020-09-11
EP3735295B1 (en) 2024-08-21

Similar Documents

Publication Publication Date Title
EP4506017A3 (en) Improved peptide pharmaceuticals for treatment of nash and other disorders
Liu et al. A review of bioactive plant polysaccharides: Biological activities, functionalization, and biomedical applications
Liu et al. Structure–activity relationships among antifungal nylon-3 polymers: identification of materials active against drug-resistant strains of Candida albicans
WO2018185131A3 (en) Oligomer extended insulin-fc conjugates
EP3733659A4 (en) AROMATIC VINYL OR ETHYL AROMATIC DERIVATIVE, RELATED PREPARATION PROCESS, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND APPLICATION
EP2799447A3 (en) Glucagon analogues
WO2008103354A3 (en) Modulators of acetyl-coenzyme a carboxylase and methods of use thereof
CL2007001006A1 (en) COMPOUNDS DERIVED FROM PIPERIDINE U 8-AZA-BICICLO [3.2.1] OCTANO SUBSTITUTED; PHARMACEUTICAL FORMULATION; PRODUCT; AND USE FOR THE TREATMENT OR PREVENTION OF DISEASES AS DEPENDENT MELLITUS DIABETES, ARTHRITIS, OBESITY, DISLIPID
EA201692466A1 (en) FATTY ACIDS AND THEIR APPLICATION FOR CONJUGATION WITH BIOMOLECULES
NZ593813A (en) Glucagon analogues
WO2016105118A3 (en) Biaryl derivative as gpr120 agonist
RU2014112223A (en) METHOD FOR PREVENTION AND / OR TREATMENT OF INSULIN RESISTANCE
MY159058A (en) Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agent
SG11201510750XA (en) Treatment of obesity, the metabolic syndrome, type 2 diabetes, cardiovascular diseases, dementia, alzheimer's disease and inflammatory bowel disease by using at least one bacterial strain from prevotella
WO2011083999A3 (en) Biguanide derivative, preparation method thereof, and pharmaceutical composition containing same as an active ingredient
PH12020550050A1 (en) Novel acylated insulin analogues and uses thereof
EP4606428A3 (en) Heparin-associated polypeptides and uses thereof
WO2018023072A3 (en) Compounds and compositions and uses thereof
WO2015128403A3 (en) An a22k, desb27, b29r, des b30, at epsilon position of lysine 22 acylated human insulin analogue
CY1110896T1 (en) A NEW ANTIFICIAL COMPOSITION
WO2017041001A3 (en) Insulin immunoglobulin fusion proteins
TR201909078T4 (en) Chemical compounds and their use for muscle quality improvement.
WO2018169282A3 (en) Pharmaceutical composition containing atpif1 for treatment of diabetes
WO2018093238A3 (en) Composition comprising as active ingredient strain having excellent ability to produce formic acid for preventing or treating obesity or metabolic syndromes caused by obesity
MX383582B (en) SULPHONAMIDES AS AGONISTS OF GPR40 AND GPR120.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 3735295

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0047540000

Ipc: A61K0038260000

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/54 20170101ALI20250404BHEP

Ipc: A61K 45/06 20060101ALI20250404BHEP

Ipc: A61K 47/64 20170101ALI20250404BHEP

Ipc: A61P 13/12 20060101ALI20250404BHEP

Ipc: A61P 1/16 20060101ALI20250404BHEP

Ipc: A61K 31/351 20060101ALI20250404BHEP

Ipc: A61K 38/02 20060101ALI20250404BHEP

Ipc: A61K 38/26 20060101AFI20250404BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251114